Skip to content

The Impact of Vitamin D and Calcium on Benign Gynecological Diseases: A Prospective, Observational Study

The Impact of Vitamin D and Calcium on Benign Gynecological Diseases: A Prospective, Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109860
Enrollment
Unknown
Registered
2025-09-26
Start date
2025-10-30
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign gynecological diseases

Interventions

Benign gynecological diseases:Recruit patients with benign gynecological diseases (endometriosis, adenomyosis, uterine fibroids, ovarian cysts, etc.), with an anticipated enrollment of 90 patients for

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18 to 79; 2. Patients diagnosed with benign gynecological diseases by histology or cytology (Endometriosis, adenomyosis, uterine fibroids, ovarian cysts, etc); 3. Patients who have written and signed the informed consent form and are eligible for follow-up; 4. Patients with acceptable liver and kidney functions; 5. Patients who are taking vitamin D and calcium supplements regularly.

Exclusion criteria

Exclusion criteria: 1. Currently pregnant patients; 2. Patients participating in other clinical trials; 3. Patients or their families refused to participate in the research or there was a serious shortage of original data; 4. Patients who have suffered from other aggressive malignant tumors within two years; 5. Patients who are undergoing radiotherapy, chemotherapy or hormone therapy; 6. Patients with severe autoimmune diseases or active infections; 7. Patients with serious psychological or mental disorders; 8. Patients with hereditary vitamin D metabolic disorders or calcium metabolism-related hereditary diseases; 9. Any other situation that the researchers consider may put the patients at risk or seriously affect the safety assessment of the patients or the interpretation of the results.

Design outcomes

Primary

MeasureTime frame
Quality of Life Score (WHOQOL-BREF);

Secondary

MeasureTime frame
25(OH) D level;Bone mineral density;Adverse events (including various adverse reactions caused by the patient's own anti-tumor therapy as well as intake of vitamin D and calcium);

Countries

China

Contacts

Public ContactMu Xiaoling

The First Affiliated Hospital of Chongqing Medical University

mxl@hospital.cqmu.edu.cn+86 189 8328 9859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026